- Raised $3M funding round led by eHealth Ventures, Aug 2024
- Raised $2.7M grant, Jan 2022
- Raised $1.1M funding round, Jan 2021
About
Founded in 2014, DreaMed pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world’s first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps.
DreaMed's mission is to unlock and scale medical knowledge so that every person living with diabetes can access personalized, expert-level care when and where it’s needed. We strive to achieve this mission by creating software that uses advanced AI and analytics to transform the massive amounts of patient data available into expert-level treatment recommendations, and to do this at a global scale. DreaMed’s product, endo.digital, is a cloud-based SAAS platform that gives healthcare organizations an end-to-end diabetes care pathway solution that can be deployed across all care settings where patients with diabetes are treated, both remotely and in person. It is the only decision support software cleared by the FDA to support both Type 1 and Type 2 diabetes.
DreaMed's founders are physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards.
Funding history · 6 rounds · $16.8M total
Q&A
- What is DreaMed Diabetes' primary focus?
- DreaMed Diabetes specializes in personalized diabetes treatment optimization solutions, developing decision-support tools and a cloud-based SaaS platform called endo.digital for diabetes management.
- When was DreaMed Diabetes founded?
- DreaMed Diabetes was founded in March 2014.
- How many employees does DreaMed Diabetes have?
- DreaMed Diabetes has 11-50 employees.
- What is DreaMed Diabetes' total funding to date?
- DreaMed Diabetes has raised a total of $16.8 million USD across multiple funding rounds.
- When was DreaMed Diabetes' most recent funding round and who were the lead investors?
- DreaMed Diabetes' most recent funding round occurred in August 2024, with eHealth Ventures as a lead investor.
- Which investors participated in DreaMed Diabetes' July 2016 funding round?
- In July 2016, Medtronic and OurCrowd participated in a funding round for DreaMed Diabetes.
- What is DreaMed Diabetes' flagship product?
- DreaMed Diabetes' flagship product is endo.digital, a cloud-based SaaS platform that provides an end-to-end diabetes care pathway solution.
- What unique regulatory clearance does DreaMed Diabetes hold for its product?
- DreaMed Diabetes is the first and only company to receive FDA clearance for a decision support system that uses data from CGM/SMBG and insulin pumps, supporting both Type 1 and Type 2 diabetes.
Team · 8
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | dreamed.ai/ |
|---|---|
| linkedin.com/company/5220173 | |
| facebook.com/pages/DreaMed-Diabetes/686958088038870 | |
| YouTube | youtube.com/channel/UC7atXxpifFgbyfRMzm5CTKw/?sub_confirmati |
Identifiers & details
| Founded | 2014-3 |
|---|---|
| Employees (exact) | 50 |
Radar intelligence
Patents
| EPO | 5 |
|---|
GitHub
| Top repos | uploader-stg-releases, node-data-tools, uploader-qa-releases, uploader-clinical-releases, uploader-releases |
|---|
Web history (Wayback)
| Domain | dreamed.ai |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|